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T he early diagnosis of pancreatic cancer is very difficult,  and the prognosis of this cancer is poor.  
Advanced pancreatic cancer is the fifth leading cause of 
cancer-related death,  carrying a devastating prognosis 
with a 5-year survival rate of 6% [1-3].  The length of a 
pancreatic cancer patient’s survival is greatly influenced 
by the disease stage,  but a few other markers of survival 
have been well characterized.  A high baseline serum 
concentration of the tumor marker CA 19-9 has been 
identified as a negative prognostic factor in patients 
with pancreatic cancer [4 , 5].  There is some evidence 
that men with this cancer have an increased risk of 
death compared to women [5],  but this association was 
not confirmed by another group [6].
In recent years,  it has become apparent that over-
weight and obesity,  as defined by body mass index 
(BMI),  is a risk factor for pancreatic cancer [7-10].  The 
mechanisms underlying this association are not fully 
elucidated,  but hyperinsulinemia and insulin resistance 
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The impact of body mass index (BMI) on postoperative survival in Japanese patients with pancreatic cancer is 
unclear.  We examined the relationship between preoperative BMI and the prognosis of Japanese patients who 
underwent surgery for pancreatic cancer to determine whether BMI affects these patients’ prognosis.  Of the 
patients who underwent pancreatectomy between January 2004 and August 2015 at our institution,  246 were 
pathologically diagnosed with pancreatic tubular adenocarcinoma; the cancer was located in the pancreatic 
head (n = 161) and in the body and tail (n = 85).  We classified the patients by BMI: underweight (n = 22),  nor-
mal weight (n = 190),  and overweight/obese (n = 34) groups.  We retrospectively analyzed medical records for 
patient characteristics,  lesion location,  disease stage,  postoperative complications,  chemotherapy,  and prog-
nosis.  Lesion location,  disease stage,  postoperative complications,  and chemotherapy were not significantly 
different among the BMI groups.  The median survival times were as follows (days): all patients,  686; under-
weight,  485; normal weight,  694; and overweight/obese,  839.  In a multivariate analysis,  after adjusting for 
competing risk factors,  low BMI was associated with an increased risk of death (normal weight: HR 0.58,  
p= 0.038; overweight/obese: HR 0.54,  p= 0.059).  High BMI was not found to be a postoperative factor for 
poor prognosis in Japanese pancreatic cancer patients.
Key words:  pancreatic cancer,  BMI,  prognosis,  surgery,  risk factor
Received August 1, 2017 ; accepted November 17, 2017.
＊Corresponding author. Phone : +81-86-252-2211; Fax : +81-86-252-7375
E-mail : sktng334@yahoo.co.jp (M. Fujii)
Conflict of Interest Disclosures: No potential conflict of interest relevant 
to this article was reported.
are considered key factors [11-14].  The number of 
overweight individuals has increased dramatically 
worldwide; it is estimated that today there are approx.  
1.6 billion individuals in the world who are overweight 
and 400 million who are obese [15 , 16].  High BMI 
―both overweight and obesity― is a well-recognized 
risk factor for several chronic degenerative diseases 
such as cardiovascular disease and diabetes and a num-
ber of types of cancer,  including pancreatic cancer.  
According to the most recent 2014 Cancer Progress 
Report from the American Association for Cancer 
Research,  a high BMI is responsible for nearly 25% of 
the relative contribution to cancer incidence,  ranking 
second only to tobacco use [17 , 18].
There are few reports regarding the effects of high 
BMI on the prognosis of pancreatic cancer patients,  
and a consensus has yet to be obtained.  The numbers of 
overweight patients who are candidates for a pancre-
atectomy has increased,  but the data concerning short-
term and long-term outcomes for this procedure in 
overweight patients are lacking [16].  There is also little 
information about the relationship between BMI and 
the postoperative prognosis of Japanese patients with 
pancreatic cancer.  In the present study,  we examined 
the relationship between preoperative BMI and progno-
sis in Japanese patients who underwent surgery for 
pancreatic cancer at our hospital,  to clarify whether 
high BMI affects the postoperative prognosis of 
Japanese individuals with pancreatic cancer.
Patients and Methods
Patients. Patients who underwent pancreatec-
tomy at Okayama Saiseikai General Hospital between 
January 2004 and August 2015 were identified.  We 
excluded cases with no follow-up records,  cases with 
incomplete complication information,  cases without 
records of postoperative therapies,  and cases with 
incomplete BMI data.  Patients whose tumors were 
identified as other than adenocarcinoma were excluded 
from study.  A final total of 246 patients who were 
pathologically diagnosed with pancreatic tubular ade-
nocarcinoma postoperatively were analyzed in this 
study.  Among these,  the cancer was located in the pan-
creatic head in 161 cases and in the body and tail in 85.
Methods. Each patient’s BMI was calculated as 
weight in kilograms (kg) divided by height in meters 
squared (m2),  both of which were measured upon 
admittance to our hospital for pancreatic cancer sur-
gery.  For the purpose of the analyses,  we divided the 
patients into 3 groups based on their BMI values: un-
derweight (BMI < 18.5 kg/m2),  normal weight (BMI 
≥ 18.5 kg/m2 and < 25 kg/m2),  and overweight/obese 
(BMI ≥ 25 kg/m2) as described by the World Health 
Organization classification.
We retrospectively examined the patients’ medical 
records to determine the patient characteristics,  lesion 
location,  disease stage,  postoperative complications,  
chemotherapy,  and prognosis in each group.  We diag-
nosed the disease stage by the Union for International 
Cancer Control (UICC) classification system based on 
the postoperative pathological diagnosis.  Regarding the 
surgical method,  pylorus-preserving and subtotal 
stomach-preserving pancreaticoduodenectomies were 
treated as pancreatoduodenectomy.  Postoperative com-
plications were evaluated according to the number of 
postoperative mortalities occurring within 90 days of 
the surgery.  Regarding the chemotherapy,  we analyzed 
the cases of the patients who underwent preoperative or 
postoperative chemotherapy for > 2 months.  Generally,  
S1 or gemcitabine-based chemotherapy had been used.  
The patients’ prognoses were evaluated based on the 
postoperative median survival time (MST).
Statistical methods. Statistical analyses were per-
formed using STATA 13 software (StataCorp,  College 
Station,  TX,  USA).  Student’s test was used to compare 
the means of the continuous variables,  and Fisher’s 
exact test was used to compare the frequencies of the 
categorical variables between groups.  The Kaplan-
Meier method and log-rank test were used to analyze 
the survival time (time from surgery until death,  
regardless of cause).  After we performed a univariate 
analysis,  we subjected the significant variables to a mul-
tivariate analysis using a Cox proportional hazards 
model.  We accepted p-values < 0.05 as significant.  This 
retrospective study was approved by the Institutional 
Review Board at Okayama Saiseikai General Hospital 
(no. 160306).
Results
The patients’ background characteristics are pre-
sented in Table 1.  Within the group of 246 patients,  
9.0% (n = 22) were underweight,  77.2% (n = 190) were 
normal weight,  and 13.8% (n = 34) were overweight/
obese.  Regarding the sex ratio (numbers of males/
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females),  the underweight group was 8/14 cases,  the 
normal weight group 100/90 cases,  and the overweight/
obese group was 19/15 cases (p = 0.32).  The median age 
of the patients was 71 (47-84) years in the underweight 
group,  69 (33-88) years in the normal weight group,  
and 70 (46-87) years in the overweight/obese group 
(p = 0.44).  The lesion was located in the pancreatic 
head/body and tail in 17/5 cases in the underweight 
group,  125/65 cases in the normal weight group,  and 
in 19/15 cases in the overweight/obese group (p = 0.28).
No significant differences in underlying disease such 
as hypertension,  hyperlipidemia,  coronary artery dis-
ease,  cerebrovascular disease,  chronic hepatitis,  chronic 
lung disease,  or previous history of cancer were observed 
among the 3 groups.  A preoperative HbA1c level 
(National Glycohemoglobin Standardization Program 
units [NGSP]) of ≥ 6.5% was observed in 8 of the 18 
patients in the underweight group,  69 of the 145 
patients in the normal weight group,  and 13 of the 29 
patients in the overweight/obese group (p = 0.90).  
However,  the preoperative HbA1c level was not mea-
sured in 34 pancreatic head cancer cases or in 20 pan-
creatic body and tail cancer cases.  The disease stage of 
the pancreatic cancer cases was I,  II/III,  or IV in 13/9 
patients in the underweight group,  87/103 patients in 
the normal weight group,  and 15/19 patients in the 
overweight/obese group (p = 0.49).
The surgical method was pancreatoduodenectomy 
in 167 cases,  body and tail pancreatectomy in 76 cases,  
pancreatic partial resection in 2 cases,  and pancreatic 
total resection in 1 case.  Mortality within 90 days 
occurred in 8 of the 246 patients (3.3%).  All 8 of these 
patients (6 pancreatic head patients and 2 body and tail 
cancer patients) underwent a pancreatoduodenectomy.  
There were no significant differences in mortality 
among the three BMI groups.
With regard to chemotherapy,  preoperative or post-
operative chemotherapy was performed in 203 of the 
246 patients (82.5%),  was 17 of the 22 underweight 
patients,  157 of the 190 normal-weight patients,  and 
29 of the 34 overweight/obese patients (p = 0.73).
With regard to long-term outcomes,  the 1-,  3-,  and 
5-year overall survival rates of the total series of patients 
following pancreatectomy were 72%,  34%,  and 24%,  
respectively,  with a median survival of 686 days.  The 
MST of the patients was 485 days in the underweight 
group,  694 days in the normal weight group,  and 839 
days in the overweight/obese group (Fig. 1).  Log-rank 
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Table 1　Baseline characteristics of the study population of Japanese patients with pancreatic cancer
No. (％)
P-value
All patients Underweight Normal weight Overweight/Obese
No. of patients 246 22 190 34
Population Characteristics
Sex (male) 127 (51.6) 8 (36.4) 100 (52.6) 19 (55.9) 0.32
Age (median,  year) 70 (33-88) 71 (47-84) 69 (33-88) 70 (46-87) 0.44
Lesion location (head/body and tail) 161/85 17/5 125/65 19/15 0.28
Underlying disease
hypertension 90 (36.6) 5 (22.7) 67 (35.3) 18 (52.9) 0.05
hyperlipidemia 22 (8.9) 1 (4.5) 20 (10.5) 1 (2.9) 0.23
coronary artery disease 13 (5.3) 1 (4.5) 8 (4.2) 4 (11.8) 0.19
cerebrovascular disease 14 (5.7) 1 (4.5) 11 (5.8) 2 (5.9) 0.97
chronic hepatitis 17 (6.9) 2 (9.1) 14 (7.4) 1 (2.9) 0.59
chronic lung disease 2 (0.8) 0 (0) 2 (1.1) 0 (0) 0.74
previous history of cancer 117 (47.6) 12 (54.5) 92 (48.4) 13 (38.2) 0.43
HbA1c≧6.5 90/192 (46.9) 8/18 (44.4) 69/145 (47.6) 13/29 (44.8) 0.94
pStage (UICC) 0.49
pStageⅠ-Ⅱ 115 (46.7) 13 (59.1) 87 (45.8) 15 (44.1)
pStageⅢ-Ⅳ 131 (53.3) 9 (40.9) 103 (54.2) 19 (55.9)
Mortality
mortality within postoperative 90 days 8 (3.3) 2 (9.1) 4 (2.1) 2 (5.9) 0.07
Chemotherapy 0.73
Existence 203 (82.5) 17 (77.3) 157 (82.6) 29 (85.3)
non-existence 43 (17.5) 5 (22.7) 33 (17.4) 5 (14.7)
tests showed a tendency of poor prognosis in the 
underweight patients (p = 0.07) (Table 2).
The univariate analysis for survival rates identified 
the following 4 parameters as significant predictors:  
lesion location (head/body and tail) (hazard ratio [HR] 
0.57,  95% confidence interval [CI] 0.41-0.80,  
p = 0.001),  disease stage (I,  II/III,  IV) (HR 1.3,  95%CI 
0.96-1.76,  p = 0.085),  chemotherapy (existence/
non-existence) (HR 2.21,  95%CI 1.55-3.15,  p < 0.001),  
and BMI (underweight/normal weight/overweight,  
obese) (HR 0.6/0.5,  95%CI 0.37-0.99/0.27-0.94,  
p = 0.044/0.029).  The multivariate analysis indicated 
that the same 4 following factors were significantly 
associated with the patients’ prognoses: lesion location 
(head/body and tail) (HR 0.59,  95%CI 0.42-0.83,  
p=0.002),  disease stage (I,  II/III,  IV) (HR 1.63,  95%CI 
1.18-2.25,  p = 0.003),  chemotherapy (existence/non- 
existence) (HR 2.85,  95%CI 1.85-4.40,  p < 0.001),  BMI 
(underweight/normal weight/overweight,  obese) (HR 
0.58/0.54,  95%CI 0.35-0.97/0.28-1.02,  p = 0.038/0.059) 
(Table 3).  Thus,  the pancreatic head lesion location,  an 
advanced disease stage,  the non-use of chemotherapy,  
and underweight were associated with a poor prognosis.  
An overweight/obese body weight was not a factor for 
poor prognosis.  In addition,  age and sex were not 
poor-prognosis factors.
Discussion
The morbidity and mortality rates of pancreatic can-
cer have increased annually,  and the prevalence of pan-
creatic cancer is expected to increase in the future [19].  
It has been suggested that pancreatic cancer is related to 
lifestyle-related diseases such as obesity and diabetes,  
and it has been made clear that excess body weight is a 
risk factor for pancreatic cancer [7-10].  In individuals 
with excess body weight,  the level of adiponectin (an 
anti-inflammatory cytokine) is decreased,  whereas the 
level of leptin (an inflammatory cytokine) is increased,  
thereby promoting insulin resistance.  Hyperinsulinism 
and high levels of blood-activated insulin-like growth 
factor 1 (IGF-1) result from insulin resistance and can 
contribute to tumor promotion through the resultant 
activation of cell proliferation,  apoptosis and angiogen-
esis.  Pancreatic cancer growth is subsequently pro-
moted.
Despite these suggested theories [11-14],  there have 
been few reports regarding the influence of excess body 
weight on the prognosis of pancreatic cancer,  and the 
findings from these studies have been controversial 
[20 , 21].  In addition,  there are few reports from Japan 
about the relationship between BMI and the postopera-
tive prognosis of pancreatic cancer.
Our present analyses revealed that excess body 
weight was not a factor for poor prognosis in Japanese 
patients with pancreatic cancer who underwent surgery.  
This result is similar to the findings of Gaujoux et al.  
and Tasi et al.,  who reported that excess body weight 
was not a poor prognostic factor in patients who under-
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Table 2　 Survival according to BMI (underweight,  normal,  and overweight/obese)
No. of patients 1-year survival rate (95%CI) 5-year survival rate (95%CI) MST,  day (95%CI)
All patients 246 72 (66-78) 24 (18-30) 686 (583-839)
underweight 22 71 (47-86) 0 485 (224-989)
normal weight 190 71 (64-77) 26 (19-33) 694 (581-906)
overweight/obese 34 82 (64-91) 31 (15-48) 839 (581-906)















Overall survival by BMI
Fig. 1　 The MSTs were 485,  694,  and 839 days in the under-
weight,  normal weight,  and overweight/obese groups,  respectively.  
Log-rank tests showed a tendency of poor prognosis in the under-
weight pancreatic cancer cases (p＝0.07).
went pancreatoduodenectomy for pancreatic cancer 
[22-24].  Most of the studies that have compared sur-
vival rates between obese and nonobese patients with 
pancreatic cancer have been limited to patients who 
underwent a pancreaticoduodenectomy,  and there have 
been few reports involving cases with pancreatic body 
and tail cancer.
In the present investigation,  there were no signifi-
cant differences among the weight groups in terms of 
patient characteristics,  disease stage,  postoperative 
complications,  or chemotherapy in both the subgroup 
of patients with pancreatic head lesions and those with 
body and tail lesions.  Stage III/IV disease was present 
in 47.8% of the pancreatic head cancer group and 
63.5% of the body and tail cancer group.  Many of the 
patients had advanced-stage disease,  because it is diffi-
cult to diagnose pancreatic cancer during the early 
stages.  As far as postoperative complications,  there 
were no significant differences in the number of mortal-
ities occurring within 90 days among the three BMI 
groups.  We did not examine perioperative stress param-
eters such as the operation time or the amount of blood 
loss; however,  the 90-day mortality rate was 3.3%,  
which is low,  and surgery had little influence on the 
prognosis.
Tasi et al.  reported that of the perioperative compli-
cations evaluated,  only pancreatic fluid leakage from a 
fistula differed significantly according to their patients’ 
BMI values,  and other complications generally did not 
show a significant difference according to BMI [22 , 25].  
It is also believed that the surgical skills for pancreatic 
cancer have improved in high-volume centers over 
recent years.
In this study,  the MST was longer in the over-
weight/obese group,  and the underweight patients had 
poorer prognoses.  A more advanced disease stage was 
also associated with a poorer prognosis.  The poor prog-
noses of our underweight pancreatic cancer patients 
may have been caused by poor nutrition.  Because we 
could not examine the patients’ nutrition conditions in 
detail in this study,  this is an issue to be addressed in 
the future.  It has been suggested that,  in general,  obe-
sity is associated with the risk of postoperative compli-
cations in the short term [26 , 27] but is not a poor 
prognostic factor in the long term.  Our results showed 
no relationship between the prognosis of pancreatic 
cancer in Japanese individuals and excess body weight.
A limitation of this study is its retrospective design 
from a single institution.  We did not examine meta-
bolic syndrome,  patient lifestyle factors (diet,  smoking,  
alcohol intake,  exercise,  etc.),  longitudinal changes in 
body weight (e.g.,  history of obesity or underweight),  or 
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Table 3　 Factors related to the survival of japanese patients with pancreatic cancer
Variable
Univariate analysis Multivariate analysis
Hazard ratio 95%CI p-value Hazard ratio 95%CI p-value
Sex
　male 1 1
　female 0.86 0.64-1.16 　0.326 0.83 0.61-1.13 0.235
Age (year)
　＜80 1 1
　≧80 1.10 0.70-1.72 　0.680 0.71 0.41-1.22 0.212
Lesion location
　head 1 1
　body and tail 0.57 0.41-0.80 　0.001 0.59 0.42-0.83 0.002
pStage (UICC)
　pStageⅠ-Ⅱ 1 1
　pStageⅢ-Ⅳ 1.30 0.96-1.76 　0.085 1.63 1.18-2.25 0.003
Chemotherapy
　existence 1 1
　non-existence 2.21 1.55-3.15 ＜0.001 2.85 1.85-4.40 ＜0.001
BMI
　underweight 1 1
　normal weight 0.60 0.37-0.99 　0.044 0.58 0.35-0.97 0.038
　overweight/obese 0.50 0.27-0.94 　0.029 0.54 0.28-1.02 0.059
concurrent medico-surgical illnesses.  In addition,  the 
numbers of cases in the underweight and overweight/
obese groups were very small (n = 22 and n = 34,  
respectively).  The obese population in Japan is small 
compared to those in Europe and the U.S.  In Japan,  the 
obesity rate is reported to be 28.7% in males and 21.3% 
in females,  and the underweight rate is 4.5% in males 
and 10.4% in females [28].  In the present patient series,  
the percentage of overweight/obese patients was 13.8%,  
which is lower than that in a previous study.  Because 
each patient’s BMI was measured just before surgery in 
the present study,  weight loss due to disease progres-
sion was also a possibility.  Moreover,  a greater number 
of cases is necessary for more precise results.  
Preoperative or postoperative chemotherapy was per-
formed in approx.  80% of our patients,  and the chemo-
therapy was shown to be an independent factor for 
overall survival.
In conclusion,  our study revealed that excess body 
weight does not carry prognostic significance in 
Japanese patients with pancreatic cancer who undergo 
pancreatectomy.  Additional studies are needed to fur-
ther investigate the prognostic significance of other 
factors in such patients.
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